ST6GAL1 and acute lymphoblastic leukemia: Similar results were previously obtained using BCP-ALL cells overexpressing ST6Gal1, for which OP9 Galectin-1 KO cells provided comparable or better chemoprotection than wild-type OP9 cells [58].